{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:49:59Z","timestamp":1770997799763,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:00:00Z","timestamp":1410825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc."}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.schres.2014.09.019","type":"journal-article","created":{"date-parts":[[2014,10,4]],"date-time":"2014-10-04T14:30:45Z","timestamp":1412433045000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies"],"prefix":"10.1016","volume":"159","author":[{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Eramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Feng","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Peters-Strickland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela P.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.09.019_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/NDT.S36438","article-title":"Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics","volume":"9","author":"Alphs","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.schres.2014.09.019_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200826020-00005","article-title":"The burden of schizophrenia on caregivers: a review","volume":"26","author":"Awad","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.schres.2014.09.019_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2014.09.019_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: a double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.09.019_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2012.03.025","article-title":"Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation","volume":"140","author":"Harvey","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.09.019_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nbd.2012.10.022","article-title":"Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia","volume":"53","author":"Harvey","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.schres.2014.09.019_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.019_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1471-244X-12-222","article-title":"Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study","volume":"12","author":"Haynes","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.09.019_bb0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2007.01.014","article-title":"Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders","volume":"93","author":"Helldin","year":"2007","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2014.09.019_bb0050","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.pnpbp.2009.03.034","article-title":"The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study","volume":"33","author":"Hong","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.09.019_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2014.09.019_bb0060","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.019_bb0065","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2014.09.019_bb0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eurpsy.2011.01.012","article-title":"Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia","volume":"27","author":"Karow","year":"2012","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.09.019_bb0075","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.ehrm.2012.06.003","article-title":"Health care utilization and costs among medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses","volume":"3","author":"Karve","year":"2012","journal-title":"Health Outcomes Res. Med."},{"issue":"4","key":"10.1016\/j.schres.2014.09.019_bb0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.09.019_bb0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2014.09.019_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.schres.2014.09.019_bb0095","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2014.09.019_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective","volume":"27","author":"Rauch","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2014.09.019_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2011.06.016","article-title":"Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone","volume":"132","author":"Sliwa","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.09.019_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"Schizophrenia, \u201cjust the facts\u201d 5. Treatment and prevention. Past, present, and future","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2014.09.019_bb0115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414005040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414005040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T23:39:54Z","timestamp":1650325194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414005040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":23,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0920996414005040"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.09.019","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}